217 related articles for article (PubMed ID: 37140985)
1. Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.
Jiang C; Kumar A; Yu Z; Shipman T; Wang Y; McKay RM; Xing C; Le LQ
J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37140985
[TBL] [Abstract][Full Text] [Related]
2. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage.
Jackson M; Ahmari N; Wu J; Rizvi TA; Fugate E; Kim MO; Dombi E; Arnhof H; Boehmelt G; Düchs MJ; Long CJ; Maier U; Trapani F; Hofmann MH; Ratner N
J Pharmacol Exp Ther; 2023 May; 385(2):106-116. PubMed ID: 36849412
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
[No Abstract] [Full Text] [Related]
4. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
[TBL] [Abstract][Full Text] [Related]
5. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
6. Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
Flint AC; Mitchell DK; Angus SP; Smith AE; Bessler W; Jiang L; Mang H; Li X; Lu Q; Rodriguez B; Sandusky GE; Masters AR; Zhang C; Dang P; Koenig J; Johnson GL; Shen W; Liu J; Aggarwal A; Donoho GP; Willard MD; Bhagwat SV; Clapp DW; Rhodes SD
Clin Cancer Res; 2023 Sep; 29(17):3438-3456. PubMed ID: 37406085
[TBL] [Abstract][Full Text] [Related]
7. A molecular basis for neurofibroma-associated skeletal manifestations in NF1.
Ma Y; Gross AM; Dombi E; Pemov A; Choi K; Chaney K; Rhodes SD; Angus SP; Sciaky N; Clapp DW; Ratner N; Widemann BC; Rios JJ; Elefteriou F
Genet Med; 2020 Nov; 22(11):1786-1793. PubMed ID: 32601387
[TBL] [Abstract][Full Text] [Related]
8. Current status of MEK inhibitors in the treatment of plexiform neurofibromas.
Gross AM; Dombi E; Widemann BC
Childs Nerv Syst; 2020 Oct; 36(10):2443-2452. PubMed ID: 32607696
[TBL] [Abstract][Full Text] [Related]
9. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells.
Mashour GA; Ratner N; Khan GA; Wang HL; Martuza RL; Kurtz A
Oncogene; 2001 Jan; 20(1):97-105. PubMed ID: 11244508
[TBL] [Abstract][Full Text] [Related]
10. Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.
Yang FC; Chen S; Clegg T; Li X; Morgan T; Estwick SA; Yuan J; Khalaf W; Burgin S; Travers J; Parada LF; Ingram DA; Clapp DW
Hum Mol Genet; 2006 Aug; 15(16):2421-37. PubMed ID: 16835260
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Neurofibroma Heterogeneity: Factors that Influence Tumor Burden in Neurofibromatosis Type 1.
Jiang C; McKay RM; Lee SY; Romo CG; Blakeley JO; Haniffa M; Serra E; Steensma MR; Largaespada D; Le LQ
J Invest Dermatol; 2023 Aug; 143(8):1369-1377. PubMed ID: 37318402
[TBL] [Abstract][Full Text] [Related]
12. Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice.
Coulpier F; Pulh P; Oubrou L; Naudet J; Fertitta L; Gregoire JM; Bocquet A; Schmitt AM; Wolkenstein P; Radomska KJ; Topilko P
Transl Res; 2023 Nov; 261():16-27. PubMed ID: 37331503
[TBL] [Abstract][Full Text] [Related]
13. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
[TBL] [Abstract][Full Text] [Related]
14. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
15. Mast cells and the neurofibroma microenvironment.
Staser K; Yang FC; Clapp DW
Blood; 2010 Jul; 116(2):157-64. PubMed ID: 20233971
[TBL] [Abstract][Full Text] [Related]
16. Schwann cell derived pleiotrophin stimulates fibroblast for proliferation and excessive collagen deposition in plexiform neurofibroma.
Tian Z; Du Z; Bai G; Gong Q; You Y; Xu G; Liu J; Xiao M; Wang Y; He Y
Cancer Gene Ther; 2024 Apr; 31(4):627-640. PubMed ID: 38302728
[TBL] [Abstract][Full Text] [Related]
17. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation.
Yu Y; Choi K; Wu J; Andreassen PR; Dexheimer PJ; Keddache M; Brems H; Spinner RJ; Cancelas JA; Martin LJ; Wallace MR; Legius E; Vogel KS; Ratner N
Acta Neuropathol; 2020 Jan; 139(1):157-174. PubMed ID: 31664505
[TBL] [Abstract][Full Text] [Related]
18. Angiogenic and invasive properties of neurofibroma Schwann cells.
Sheela S; Riccardi VM; Ratner N
J Cell Biol; 1990 Aug; 111(2):645-53. PubMed ID: 1696266
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease.
Krag S; Danielsen CC; Carmeliet P; Nyengaard J; Wogensen L
Kidney Int; 2005 Dec; 68(6):2651-66. PubMed ID: 16316341
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK.
Na Y; Hall A; Choi K; Hu L; Rose J; Coover RA; Miller A; Hennigan RF; Dombi E; Kim MO; Subramanian S; Ratner N; Wu J
Oncogene; 2021 Feb; 40(5):951-963. PubMed ID: 33293695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
